Researchers at UC Davis discovered a unique genetic mutation in humans' Fas Ligand (FasL) protein that weakens immune response against solid tumors. This mutation, absent in primates, makes FasL vulnerable to tumor enzymes, reducing immunotherapy effectiveness. Blocking these enzymes could enhance cancer treatments, offering hope for better therapies against aggressive cancers.